Weekly Recap: Evonik rejects BASF bid and raises full-year targets
Evonik Industries AG (EVK) rejected BASF's €24-per-share offer, valuing it at €11.18 billion, citing an insufficient price. The company raised its full-year targets despite a weakening German chemical sector, according to Reuters.
How this was made

The 30-second read
Why it matters
The rejection removes a premium acquisition premium, likely prompting short‑term price declines for both parties and prompting investors to re‑evaluate sector exposure.
Market read
Primary M&A news with material valuation impact; immediate trading relevance for both German chemical stocks.
What to watch
Potential regulatory scrutiny or integration challenges that may have motivated Evonik's decision.
Background
The article summarizes a recent M&A negotiation where Evonik turned down BASF's improved bid and simultaneously raised its own full‑year guidance amid a weakening German chemicals market.
Ticker impact
BASF's improved €24-per-share offer was turned down by Evonik, halting its acquisition attempt.
downward pressure from the market pricing in the bid failure
The rejection of a multi‑billion‑euro offer is a material negative for BASF's M&A outlook.
Market effects
German chemicals sector may see broader valuation adjustments as the deal fallout raises M&A uncertainty.
European markets could experience modest downside pressure on related chemical stocks.
Limited to chemicals sector; no major global macro impact.
Counterpoint
If Evonik can secure better terms later, the rejection may be seen as a disciplined move, potentially supporting the stock long term.
Key entities
- CompanyEvonik Industries AG
German chemicals producer, ticker EVK.DE.
- CompanyBASF SE
World's largest chemical company, ticker BAS.DE.

